SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations.

van Donge, T; Pfister, M; Bielicki, J; Csajka, C; Rodieux, F; van den Anker, J; Fuchs, A (2018) Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations. Antimicrob Agents Chemother, 62 (4). e02004-17. ISSN 1098-6596 https://doi.org/10.1128/AAC.02004-17
SGUL Authors: Bielicki, Julia Anna

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (1MB) | Preview

Abstract

Optimal dosing of gentamicin in neonates is still a matter of debate despite its common use. We identified gentamicin dosing regimens from eight international guidelines and seven Swiss neonatal intensive care units. The dose per administration, the dosing interval, the total daily dose, and the demographic characteristics between guidelines were compared. There was considerable variability with respect to dose (4 to 6 mg/kg), dosing interval (24 h to 48 h), total daily dose (2.5 to 6 mg/kg/day), and patient demographic characteristics that were used to calculate individualized dosing regimens. A model-based simulation study in 1071 neonates was performed to determine the achievement of efficacious peak gentamicin concentrations according to predefined MICs (Cmax/MIC ≥ 10) and safe trough concentrations (Cmin ≤ 2 mg/liter) with recommended dosing regimens. MIC targets of 0.5 and 1 mg/liter were used. Dosing optimization was performed giving priority to the first day of treatment and with the goal of simplifying dosing. Current gentamicin neonatal guidelines allow to achieve effective peak concentrations for MICs ≤ 0.5 mg/liter but not higher. Model-based simulations indicate that to attain peak gentamicin concentrations of ≥10 mg/liter, a dose of 7.5 mg/kg should be administered using an extended dosing interval regimen. Trough concentrations of ≤2 mg/liter can be maintained with a dosing interval of 36 to 48 h in neonates according to gestational and postnatal age. For treatment beyond 3 days, therapeutic drug monitoring is advised to maintain adequate serum concentrations.

Item Type: Article
Additional Information: Copyright © American Society for Microbiology, Antimicrob. Agents Chemother. 62:e02004-17 doi: 10.1128/AAC.02004-17, 2018
Keywords: MIC, aminoglycosides, pediatrics, pharmacokinetics, aminoglycosides, pediatrics, pharmacokinetics, MIC, MIC, aminoglycosides, pediatrics, pharmacokinetics, Microbiology, 0605 Microbiology, 1108 Medical Microbiology, 1115 Pharmacology And Pharmaceutical Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Antimicrob Agents Chemother
ISSN: 1098-6596
Language: eng
Dates:
DateEvent
April 2018Published
21 January 2018Published Online
9 January 2018Accepted
PubMed ID: 29358294
Web of Science ID: WOS:000428392100034
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/109904
Publisher's version: https://doi.org/10.1128/AAC.02004-17

Actions (login required)

Edit Item Edit Item